Evidence map›Paper›PMID 34556083›Full record

ArticleBMC pulmonary medicine2021

Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease.

Qingling Li, Weng Wong, Andrew Birnberg, Arindam Chakrabarti, Xiaoying Yang, David F Choy, Julie Olsson, Erik Verschueren, Margaret Neighbors, Wendy Sandoval and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Qingling LiDepartment of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., South San Francisco, CA, USA.
Weng WongDepartment of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., South San Francisco, CA, USA.
Andrew BirnbergDepartment of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., South San Francisco, CA, USA.
Arindam ChakrabartiDepartment of Biomarker Discovery OMNI, Genentech, Inc., South San Francisco, CA, USA.
Xiaoying YangDepartment of Biostatistics, Genentech, Inc., South San Francisco, CA, USA.
David F ChoyDepartment of Biomarker Discovery OMNI, Genentech, Inc., South San Francisco, CA, USA.
Julie OlssonProduct Development Immunology, Infectious Disease and Ophthalmology, Genentech, Inc., South San Francisco, CA, USA.
Erik VerschuerenDepartment of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., South San Francisco, CA, USA.
Margaret NeighborsOMNI Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Wendy SandovalDepartment of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., South San Francisco, CA, USA.
Carrie M RosenbergerDepartment of Biomarker Discovery OMNI, Genentech, Inc., South San Francisco, CA, USA.
Michele A GrimbaldestonOMNI Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Gaik W TewProduct Development Immunology, Infectious Disease and Ophthalmology, Genentech, Inc., South San Francisco, CA, USA. gaikt@gene.com.
Gene Therapy Laboratory · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) exacerbations are heterogenous and profoundly impact the disease trajectory. Bioactive lipid lysophosphatidic acid (LPA) has been implicated in airway inflammation but the significance of LPA in COPD exacerbation is not known. The aim of the study was to investigate the utility of serum LPA species (LPA16:0, 18:0, 18:1, 18:2, 20:4) as biomarkers of COPD exacerbation. PATIENTS AND

methodsLPA species were measured in the baseline placebo sera of a COPD randomized controlled trial. Tertile levels of each LPA were used to assign patients into biomarker high, medium, and low subgroups. Exacerbation rate and risk were compared among the LPA subgroups.

resultsThe levels of LPA species were intercorrelated (rho 0.29-0.91). Patients with low and medium levels of LPA (LPA16:0, 20:4) had significantly higher exacerbation rate compared to the respective LPA-high patients [estimated rate per patient per year (95% CI)]: LPA16:0-low = 1.2 (0.8-1.9) (p = 0.019), LPA16:0-medium = 1.3 (0.8-2.0) (p = 0.013), LPA16:0-high = 0.5 (0.2-0.9); LPA20:4-low = 1.4 (0.9-2.1) (p = 0.0033), LPA20:4-medium = 1.2 (0.8-1.8) (p = 0.0089), LPA20:4-high = 0.4 (0.2-0.8). These patients also had earlier time to first exacerbation (hazard ratio (95% CI): LPA16:0-low = 2.6 (1.1-6.0) (p = 0.028), LPA16:0-medium = 2.7 (1.2-6.3) (p = 0.020); LPA20.4-low = 2.8 (1.2-6.6) (p = 0.017), LPA20:4-medium = 2.7 (1.2-6.4) (p = 0.021). Accordingly, these patients had a significant increased exacerbation risk compared to the respective LPA-high subgroups [odd ratio (95% CI)]: LPA16:0-low = 3.1 (1.1-8.8) (p = 0.030), LPA16:0-medium = 3.0 (1.1-8.3) (p = 0.031); LPA20:4-low = 3.8 (1.3-10.9) (p = 0.012), LPA20:4-medium = 3.3 (1.2-9.5) (p = 0.025). For the other LPA species (LPA18:0, 18:1, 18:2), the results were mixed; patients with low and medium levels of LPA18:0 and 18:2 had increased exacerbation rate, but only LPA18:0-low patients had significant increase in exacerbation risk and earlier time to first exacerbation compared to the LPA18:0-high subgroup.

conclusionsThe study provided evidence of association between systemic LPA levels and exacerbation in COPD. Patients with low and medium levels of specific LPA species (LPA16:0, 20:4) had increased exacerbation rate, risk, and earlier time to first exacerbation. These non-invasive biomarkers may aid in identifying high risk patients with dysregulated LPA pathway to inform risk management and drug development.

Indexed as

AgedBiomarkersDisease ProgressionFemaleHumansLogistic ModelsLysophospholipidsMaleMiddle AgedProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicSeverity of Illness IndexBiomarkerslysophosphatidic acidLysophospholipidsChronic obstructive pulmonary diseaseExacerbationLipidomicSerum lysophosphatidic acid species

Identifiers

PMID34556083
PMCPMC8461999
OpenAlexW3201615999

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.